Guidance for reporting economic evaluations

Reporting guidance provided for: Name of guideline website (where available) References including PMID
Cost-effectiveness analyses
Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276(16):1339-1341.
PMID: 8861994
Cost-effectiveness analyses conducted as part of clinical trials (design, conduct, reporting) ISPOR RCT-CEA Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health 2005; 8(5):521-533.
PMID: 16176491
Economic evaluation for trial-based studies and decision analytic models (design, analysis, reporting)
Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005; 21(2):165-171. PMID: 15921055
Economic evaluation (modelling studies)
Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A. Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics 1998; 14(3):259-268. PMID: 10186465
Economic evaluation studies in obstetrics (design, execution, interpretation, reporting)
Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol 2004; 191(4):1070-1076.
PMID: 15507923

Economic evaluation of haemophilia prophylaxis



Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, et al. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia 2008;14(1):127-32.
PMID: 18005148

Page last edited: 11 January 2010